Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6
Lawitz, Eric, Gane, Edward, Feld, Jordan J., Buti, Maria, Foster, Graham R., Rabinovitz, Mordechai, Burnevich, Eduard, Katchman, Helena, Tomasiewicz, Krzysztof, Lahser, Fred, Jackson, Beth, Shaughnessy, Melissa, Klopfer, Stephanie, Yeh, Wendy W., Robertson, Michael N., Hanna, George J., Barr, Eliav, Platt, Heather L., Gordon, Stuart C., Lawitz, Eric J., Ruane, Peter Jerome, Sahota, Amandeep, Terrault, Norah A., Tsai, Naoky, Kalathil, Sumodh C., Reddy, Gautham, Ghesquiere, Wayne, Borgia, Sergio, Conway, Brian, Feld, Jordan, Tsoi, Keith, Cooper, Curtis L., Ghali, Peter Maged, Thompson, Alexander James Venn, Panero, Jose Luis Calleja, Ferret, Sabela Lens Maria Buti, Franinan, Luis Margusino, Angeles Castro Iglesias, Maria, Brown, Ashley, Agarwal, Kaushik, Foster, Graham, Cramp, Matthew, Zuckerman, Eli, Veitsman, Ella, Cohen, Michal, Lurie, Yoav, Ari, Ziv Ben, Janczewska, Ewa, Szymczak, Aleksandra, Halota, Waldemar, Flisiak, Robert, Mahomed, Adam, Sonderup, Mark Wayne, Punt, Zelda Erika, Kgomo, Mpho Klaas, Bernhardi, David C, Burnevich, Eduard Z., Kizhlo, Svetlana
Published in Journal of viral hepatitis (01.09.2019)
Published in Journal of viral hepatitis (01.09.2019)
Get full text
Journal Article